Page 1261 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1247

Trimethoprim-sulfamethoxazole, 835–837, etanercept, 654f, 655 Unstable angina, 195, 208–209
840t golimumab, 654f, 655 Urantide, 316
Trimipramine maleate, 546t infliximab, 654f, 655 Urapidil, 160
Triorthocresyl phosphate (TOCP), 121, for psoriasis, 1079 Urea, 1082–1083
1011 structures of, 654f Urea transporter UT1, 259
Trioxsalen, 1076 Tumor stem cells, 948 Ureidopenicillins, 801. See also Penicillin(s)
Triptans, 289–291, 290f, 291t, 296t, 298t Tumor suppressor genes, in cancer, 949 Uric acid metabolism, 265
Triptorelin, 676 Turner syndrome, growth hormone for, Uricosuric agents, 660f, 661
1,4,5-Trisphosphate-diacylglycerol cascade, 671 Uridine 5-diphosphate (UDP)-glucuronosyl
215 Type I hypersensitivity, 982, 983f, transferases (UGTs), 63, 64f, 64t,
Troglitazone, 761 998–1000 67t, 69
Trophotropic nervous system, 100 Type II hypersensitivity, 982–983 Uridine 5′-diphosphoglucuronosyl transfer-
Tropicamide, 126f, 130t, 135t. See also Type III hypersensitivity, 983, 999–1000 ase 1 (UGT1A1), 74, 76t, 79t,
Muscarinic receptor blockers Type IV hypersensitivity, 983, 984f 81, 87
Tropisetron, antiemetic properties of, 1104 Typhoid vaccines Urinary antiseptics, 902t
Trospium, 131, 135t. See also Muscarinic Ty21a, oral, 1178t methenamine hippurate, 897, 902t
receptor blockers VI capsular polysaccharide, 1178t methenamine mandelate, 897, 902t
TRPA1, 560b Tyramine, 97f, 150, 150t nitrofurantoin, 895–896, 902t
TRPV1, 560b biosynthesis of, 97f Urinary frequency, after prostatectomy,
Trypanosomiasis drugs, 931–935, noradrenergic transmitter release by, 95 124, 136
932t–933t. See also Antiprotozoal Tyrosine, 341, 341t Urinary obstruction, alpha-receptor
drugs Tyrosine hydroxylase inhibitors, 171t antagonists for, 161
t-SNAREs, 95 Tyrosine kinase inhibitors (TKIs), 966t, Urinary pH manipulation, for poisoning,
Tuberculin hypersensitivity, 983 967 1040
Tuberculosis Tyrosine kinase receptor, 27–28, 28f Urinary retention, 118
drug-susceptible, 844t Urinary tract infection, 834, 841
with HIV, antimycobacterial drugs for, U Urodilatin, 309
842, 852 UGT1A1 pharmacogenomics, 74, 76t, 79t, Urofollitropin, 674, 683t
Tuberculosis drugs, 842–849, 851t 81, 87 Urokinase, 611, 618
ethambutol, 842, 843t, 845–846, 851t Ularitide. See also Natriuretic peptides Urotensin, 316
isoniazid, 842–845, 843t, 851t heart failure treated with, 220 Urotensin antagonists, 318t
preparations available, 852t on kidney, 259 Ursodiol, 1113, 1116t
pyrazinamide, 842, 843t, 846, 851t on vasoactive peptides, 317t Urticaria, 278, 284
rifampin, 842, 843t, 845, 851t Ultrarapid metabolism, 67 Use-dependent drug action, 236, 238f
second-line, 846–849 Ultrarapid metabolizer (UM), Ustekinumab, 656, 995, 1079
aminosalicylic acid, 843t, 848 67, 75t Uterine leiomyomata (fibroids), 677
bedaquiline, 843t, 849 Umeclidinium, 130, 354
capreomycin, 843t, 847 Unfractionated heparin (UFH), 612f, V
cycloserine, 843t, 847 612–614. See also Heparin Vaccines, 1175–1182, 1176t–1179t.
ethionamide, 843t, 847 Unicyclic agents, for depression, 549t. See also Immunization; specific
fluoroquinolones, 848 See also Antidepressant agents types
kanamycin and amikacin, 843t, 848 chemistry of, 538–539, 539f routine childhood, recommended
linezolid, 848–849 clinical pharmacology of schedule for, 1175, 1179t
rifabutin, 843t, 849 adverse effects in, 547 Vaccinia immune globulin, 1181t
rifapentine, 843t, 849 drug interactions in, 548t, 549 Vagus nerve
streptomycin, 843t, 846–847, 851t pharmacodynamics of, 542t, 543 on cardiovascular function, 100
types and dosing of, 843t pharmacokinetics of, 540t, 541 on immune function, 89
Tuberoinfundibular system, 516 preparations available, 551t Vagus nerve stimulation (VNS), for
Tubocurarine, 475, 489t. See also Unipolar depression, antipsychotics for, epilepsy, 411
Neuromuscular blocking drugs 519. See also Antipsychotic Valacyclovir
properties of, 478t agents herpes simplex virus treated with, 865t,
structure of, 476f Unithiol, 1031–1032 866–867
Tumor necrosis factor-α (TNF-α), 997t, for arsenic poisoning topical dermatologic, 1074
998 acute, 1026 varicella zoster virus treated with, 865t,
Tumor necrosis factor-α blockers, 653–656 chronic, 1027 866–867
adalimumab, 652–654, 654f for mercury poisoning Valganciclovir, 868t, 868–869
adverse effects of, 655–656 acute, 1029 Valomaciclovir, 839
certolizumab, 654f, 654–655 chronic, 1029 Valproate, 529t. See Valproic acid